Millions of people around the world suffer from neurodegenerative conditions such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, amyotrophic lateral sclerosis and Huntington’s disease. Neurodegenerative diseases primarily affect an older population, and as we continue to live longer, incidences of these are expected to soar. Finding treatments and cures for neurodegenerative diseases is therefore a goal of increasing urgency.

Advancing the development of new drugs for neurodegenerative diseases is the target for scientists brought together at the 7th Annual Drug Discovery for Neurodegeneration Conference, hosted by the Alzheimer’s Drug Discovery Foundation (ADDF).

ADDF is a public charity supporting the advancement of drugs to prevent, treat, and cure Alzheimer’s disease, related dementias, and cognitive aging.

On 10-12 February 2013, academic and industry scientists will meet up in San Francisco, USA to discuss the principles and practice of drug discovery, including high throughput screening, lead optimization, preclinical proof-of-concept, and investigational new drug (IND) enabling and regulator issues, in a range of neurodegenerative diseases. The course is designed to give participants knowledge and relevant resources about this field of scientific investigation and address the associated barriers and challenges. Educating scientists on the process of translating basic research into novel therapies is important for the advancement of treatments in neurodegenerative disease.

Alzheimer’s Research & Therapy, a journal that is also committed to helping the field develop research into therapies, publishes ADDF’s widely read meeting reports. The journal is also proud to have the Executive Director of ADDF, Professor Howard Fillit, on its international Editorial Board.

As a major forum for translational research into Alzheimer’s disease and other neurodegenerative diseases, Alzheimer’s Research & Therapy, is dedicated to publishing international peer-reviewed articles at the forefront of scientific breakthroughs in the field. To keep up to date with the latest in translational Alzheimer’s disease research, sign up to receive article alerts.